MAPT and Cognitive impairment: This suggests that AD pathology may be more widespread in patients who report cognitive impairment (so that we are more likely to see both β-amyloid and tau in a small biopsy), even if the local density of AD pathology in these biopsies is not significantly higher compared to patients who report no cognitive impairment.